Risankizumab Significantly Reduces Severity of Plaque Psoriasis Compared to Apremilast

Patients on risankizumab also reported greater satisfaction with treatment for moderate plaque psoriasis.

Related Keywords

United Kingdom ,British ,Mudra Kapoor ,Henry Ford Health System ,Boehringer Ingelheim ,British Journal ,Psoriasis Area ,Severity Index ,Static Physician ,Global Assessment ,Linda Stein Gold ,